JLE

Hématologie

MENU

Prophylaxie précoce de la rechute au niveau du système nerveux central en association à de la chimiothérapie intensive des patients atteints de lymphome B diffus à grandes cellules, une étude nordique Volume 26, numéro 4, Juillet-Août 2020

  • [1] Schmitz N., Zeynalova S., Nickelsen M. CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP. JCO. 2016;34:3150-3156.
  • [2] Gang A.O., Strøm C., Pedersen M. R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group. Ann Oncol. 2012;23:147-153.
  • [3] Holte H., Leppä S., Björkholm M. Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study. Ann Oncol. 2013;24:1385-1392.
  • [4] Leppä S., Jørgensen J., Tierens A. Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis. Blood Adv. 2020;4:1906-1915.
  • [5] Savage K.J., Slack G.W., Mottok A. Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL. Blood. 2016;127:2182-2188.